FDA guidance
Best Practices in Developing Proprietary Names for Human Nonprescription Drug Products…
FDA guidance · Draft · issued Dec 8, 2020
Key facts
| Title | Best Practices in Developing Proprietary Names for Human Nonprescription Drug Products; Draft Guidance for Industry: Draft Guidance for Industry |
|---|---|
| Status | Draft |
| Issue date | Dec 8, 2020 |
| Center | Center for Drug Evaluation and Research |
| Issuing office | Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research |
| Communication type | Guidance Document |
| Regulated product | Drugs |
| Docket number | FDA-2020-D-0770 |
| Comments close | Feb 8, 2021 |
| Open for comment | No |
| Document on fda.gov | fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents